Sun Pharma Advanced Research Company gets board approval to raise Rs 1,800 crore
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
The drug is also intended for the treatment of glioblastoma multiforme
The segment delivered strong sales growth of 20% YoY
Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Subscribe To Our Newsletter & Stay Updated